applied a novel CRP kinetics approach to nivolumab immunotherapy in metastatic renal cell carcinoma (mRCC), finding great tumour shrinkage and outcomes in ‘flare-responders’ whose CRP levels initially increased but then decreased within three months to levels below baseline (16). Here, CRP is linked to neoplasm.